Association for Research in Vision and Ophthalmology
Association for Research in Vision and Ophthalmology
April 29, 2019
1 min watch
Save

VIDEO: Alimera highlights Iluvien research at ARVO

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

VANCOUVER, British Columbia — Samer Kaba, MD, the new chief medical officer at Alimera Sciences, discusses research regarding Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg), the company’s diabetic macular edema treatment, at the Association for Research in Vision and Ophthalmology meeting.